Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.105 CHF | +1.31% | +3.97% | +132.38% |
Apr. 24 | Kuros Biosciences Posts Higher Q1 Product Sales | MT |
Apr. 17 | Kuros Biosciences AG Approves Board of Director and Committee Changes | CI |
Sales 2022 | 17.99M 19.66M | Sales 2023 | 33.56M 36.69M | Capitalization | 128M 140M |
---|---|---|---|---|---|
Net income 2022 | -14M -15.3M | Net income 2023 | -13M -14.21M | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.14M | Net cash position 2023 | 12M 13.12M | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | 80 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.77% |
1 day | +0.13% | ||
1 week | +0.50% | ||
Current month | +23.46% | ||
1 month | +16.62% | ||
3 months | +45.99% | ||
6 months | +112.20% | ||
Current year | +129.23% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 23-02-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 18-06-13 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 21-04-18 |
Joost de Bruijn
FOU | Founder | 58 | 17-12-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-27 | 8.11 | +1.38% | 71 145 |
24-05-24 | 8 | +0.13% | 66,523 |
24-05-23 | 7.99 | +0.50% | 118,615 |
24-05-22 | 7.95 | +1.92% | 86,555 |
24-05-21 | 7.8 | -2.01% | 131,797 |
Delayed Quote Swiss Exchange, May 24, 2024 at 11:30 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+129.23% | 323M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.69% | 21.78B | |
-10.60% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- KURN Stock